Geoffrey Guy, GW Pharma, Sativex History & Epidiolex Approval

The history of cannabis medicine in the modern regulatory era runs through one company: GW Pharmaceuticals. Founded by Dr. Geoffrey Guy and Dr. Brian Whittle in 1998, GW navigated a path no one had walked — growing pharmaceutical-grade cannabis under government license, conducting double-blind clinical trials, and obtaining regulatory approvals from drug agencies that had spent decades treating the plant as a controlled substance with no medical use. The story is the bridge between the underground cannabis-medicine movement and the conventional pharmaceutical industry.

Geoffrey Guy — The Founder

Geoffrey Guy was a British physician with a background in pharmaceutical development — he had previously worked on hormone replacement therapy and other licensed drugs. In 1997 he met with the UK Home Office to propose a research program: licensed cultivation of medical-grade cannabis, with the explicit goal of producing a prescription medicine that would pass UK and European regulatory scrutiny.

The Home Office’s decision in 1998 to grant Guy and his partner Brian Whittle a cultivation license was unusual. The UK was a signatory to the 1961 Single Convention; cannabis cultivation for medical research was permitted under treaty exceptions, but had not been actively pursued in the UK for decades. Guy received the license; GW Pharmaceuticals was incorporated; and the company began cultivating cannabis at a secret location in southern England.

Sativex History

GW’s first product was an oromucosal spray standardized to a 1:1 ratio of THC and CBD — 2.7 mg THC and 2.5 mg CBD per 100-microliter spray. The product was named Sativex (international nonproprietary name: nabiximols). It was developed primarily for spasticity associated with multiple sclerosis, though clinical programs also pursued cancer pain and neuropathic pain.

Sativex was the first cannabis-based prescription medicine approved by a national drug regulator anywhere in the world. The major regulatory milestones:

• 2005 — approved in Canada for neuropathic pain in MS, the first cannabis-derived prescription drug license in the modern era.
• 2010 — approved in the UK for MS spasticity.
• 2010–2014 — approved in 28 additional countries for MS spasticity, including Germany, Spain, Italy, Sweden, Denmark, the Netherlands, Switzerland, Austria, and others. Today the count is 29+ countries.
• 2014 — UK approval for MS spasticity confirmed by NICE for restricted use.

Sativex was never approved by the FDA in the United States. GW pursued a Phase III cancer-pain indication in the US, but the trial — reported in 2015 — failed to show a statistically significant benefit over placebo. The cancer-pain indication was abandoned. GW did not pursue a separate US application for the MS-spasticity indication that had succeeded in Europe.

The Sativex history is significant for two reasons. First, it proved that a botanical cannabis extract could meet the standards of randomized controlled trials, manufacturing consistency, and pharmacovigilance that pharmaceutical regulators require. Second, it created a regulatory template — demonstrating to drug agencies, payers, and clinical practice that cannabis-derived medicines could be commercialized through conventional channels.

Epidiolex Approval

GW’s second major product was a high-purity cannabidiol (CBD) oral solution — 100 mg/mL CBD in sesame oil, with the international nonproprietary name cannabidiol and the brand name Epidiolex. Development was driven by emerging evidence that CBD reduced seizure frequency in pediatric epilepsy syndromes that had no good treatment options.

The pivotal clinical program targeted two rare and severe pediatric epilepsies:

• Dravet syndrome — a catastrophic epilepsy that begins in the first year of life.
• Lennox-Gastaut syndrome — a treatment-resistant pediatric epilepsy.

The Dravet trial (Devinsky et al., NEJM 2017) showed that Epidiolex reduced convulsive seizures by approximately 39% from baseline, compared with 13% for placebo. The Lennox-Gastaut trial showed similar reductions in drop seizures.

On June 25, 2018, the FDA approved Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older. It was the first cannabis-derived drug ever approved by the FDA. The DEA subsequently rescheduled Epidiolex to Schedule V (the least restrictive controlled-substance schedule), and in 2020 fully descheduled it — making Epidiolex the only cannabis-derived medicine in US history without a controlled-substance classification.

Epidiolex’s approval for tuberous sclerosis complex followed in 2020. The drug is now standard of care for these epilepsy syndromes and has been a major commercial success.

The Charlotte Figi Connection

The Charlotte Figi story — the Colorado girl with Dravet syndrome whose seizures were dramatically reduced by a high-CBD cannabis preparation in 2012–2013 — was a cultural catalyst for CBD’s emergence into public consciousness. The Stanley brothers’ preparation that helped Charlotte was different from Epidiolex (a botanical extract rather than a pharmaceutical-grade isolate), but the clinical observation was the same: CBD reduces seizures in Dravet syndrome.

GW’s pivotal trials began enrolling in the years immediately after the Figi case became public, and the FDA approval of Epidiolex in 2018 was the pharmaceutical industry’s ratification of what families like the Figis had been telling the medical establishment for years. The activist patient story and the regulated drug approval were two halves of the same evidence accumulation.

The Jazz Pharmaceuticals Acquisition

In May 2021, Jazz Pharmaceuticals announced the acquisition of GW Pharmaceuticals for approximately $7.2 billion in cash and stock. It remains the largest acquisition in cannabis-pharmaceutical history. Jazz absorbed GW’s cultivation operations, regulatory pipeline, and the rights to Epidiolex and Sativex. The company’s research programs in additional cannabinoid medicines — for autism-associated behaviors, schizophrenia, glioblastoma, and other indications — continued under Jazz.

Geoffrey Guy stepped down from operational roles at the close of the acquisition. He has since pursued additional ventures in cannabinoid pharmaceuticals.

What GW Proved

GW Pharmaceuticals’ significance is not in the specific products. It is in what those products demonstrated. Before GW, the conventional position of every drug regulator was that cannabis-derived medicines were not feasible — that the variability of botanical material, the controlled-substance overhead, and the political risk made conventional regulatory paths unworkable. GW proved that to be wrong.

By the time Epidiolex received FDA approval in 2018, the question of whether cannabis-derived drugs could be developed under conventional pharmaceutical standards was settled. The remaining questions — how broad the indications would be, how many companies would follow GW’s template, how much of the medical-cannabis market would migrate from state programs to FDA-approved products — remain open.

Geoffrey Guy, GW Pharma, Sativex history, and Epidiolex approval together constitute the regulatory bridge between the prohibition era and the medical-pharmaceutical era of cannabis. Whatever happens next in the United States — rescheduling, FDA approval of additional cannabis medicines, a hybrid market — will be built on top of what GW established.